Nrdp1-Mediated Regulation of ErbB3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer Cells

Abstract

Patients with advanced prostate cancer (PCa) are initially susceptible to androgen withdrawal (AW), but ultimately develop resistance to this therapy (castration-resistant PCa, CRPC). Here, we show that AW can promote CRPC development by increasing the levels of the receptor tyrosine kinase ErbB3 in androgendependent PCa, resulting in AW-resistant cell cycle progression and increased androgen receptor (AR) transcriptional activity. CRPC cell lines and human PCa tissue overexpressed ErbB3, whereas downregulation of ErbB3 prevented CRPC cell growth. Investigation of the mechanism by which AW augments ErbB3, using normal prostate-derived pRNS-1-1 cells, and androgen-dependent PCa lines LNCaP, PC346C, and CWR22 mouse xenografts, revealed that the AR suppresses ErbB3 protein levels, whereas AW relieves this suppression, showing for the first time the negative regulation of ErbB3 by AR. We show that AR activation promotes ErbB3 degradation in androgen-dependent cells, and that this effect is mediated by AR-dependent transcriptional upregulation of neuregulin receptor degradation protein-1 (Nrdp1), an E3 ubiquitin ligase that targets ErbB3 for degradation but whose role in PCa has not been previously examined. Therefore, AW decreases Nrdp1 expression, promoting ErbB3 protein accumulation, and leading to AR-independent proliferation. However, in CRPC sublines of LNCaP and CWR22, which strongly overexpress the AR, ErbB3 levels remain elevated due to constitutive suppression of Nrdp1, which prevents AR regulation of Nrdp1. Our observations point to a model of CRPC development in which progression of PCa to castration resistance is associated with the inability of AR to transcriptionally regulate Nrdp1, and predict that inhibition of ErbB3 during AW may impair CRPC development. Cancer Res; 70(14); 5994-6003. ©2010 AACR.

Oligomerization of the Nrdp1 E3 Ubiquitin Ligase Is Necessary for Efficient Autoubiquitination but Not ErbB3 Ubiquitination

“…This breadth of substrates targeted by Nrdp1 suggests that the ligase is a key regulator of critical signaling proteins and gives Nrdp1 potential roles in prostate cancer (45), cardiac disease (46,47), and Parkinson disease (44) in addition to breast cancer. Thus, an understanding of the mechanisms by which Nrdp1 is regulated could shed light on the control of a variety of physiological and pathological processes.…”

Reciprocal cross-regulation between RNF41 and USP8 controls cytokine receptor sorting and processing

“…Since RNF41 affects USP8 and ESCRT-0 stability, a more generic role for RNF41 on cargo sorting seems plausible, which will be the subject for further investigation. Moreover, imbalance between RNF41 and USP8 levels in the context of cytokine receptors and other proteins is medically relevant as aberrant RNF41 expression is linked to the onset of breast cancer, prostate cancer and chronic lymphocytic leukemia (CLL), while USP8 is a multiple myeloma survival factor (Chen et al, 2010;Hanlon et al, 2009;Tiedemann et al, 2012;Yen et al, 2006).…”

HER3/ErbB3, an emerging cancer therapeutic target

“…A RING finger E3 ubiquitin ligase Nrdp1 has been reported to interact with HER3 and promotes HER3 ubiquitination and degradation via proteasome in breast and prostate cancer cells [58,59]. Our recent study identified E3 ubiquitin ligase NEDD4 as a novel interaction partner of HER3 [60].…”